Market research
GSS.AU Genetic Signatures Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 18M
- P/E ratio
- Not available
- Analyst target
- 0.31
- Dividend yield
- Not available
- Beta
- 0.58
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- AU000000GSS4
- Market cap
- 18M
- P/E ratio
- Not available
- Analyst target
- 0.31
- Dividend yield
- Not available
- Beta
- 0.58
About
About Genetic Signatures Limited
Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. The company offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name. Genetic Signatures Limited was incorporated in 2001 and is headquartered in Newtown, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GSS.AU discussion.
5 years, 5 months ago
Genetic Signatures Limited is currently in a long term downtrend where the price is trading 14.5% below its 200 day moving average.
From a valuation standpoint, the stock is 96.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.2.
Genetic Signatures Limited's total revenue rose by 409.5% to $19M since the same quarter in the previous year.
Its net income has increased by 291.7% to $4M since the same quarter in the previous year.
Finally, its free cash flow grew by 371.5% to $3M since the same quarter in the previous year.
Based on the above factors, Genetic Signatures Limited gets an overall score of 4/5.